



Cytisinicline for Smoking Cessation

Draft Questions for Deliberation and Voting: January 15th Public Meeting

These questions are intended for the deliberation of the Midwest CEPAC voting body at the public meeting.

Patient Population for questions 1-3: *Adults who are interested in quitting cigarettes*

Clinical Evidence

1. For people who smoke, is the current evidence adequate to demonstrate that the net health benefit of cytinicline is greater than that of behavioral support alone?

Yes No

2. For people who smoke, is the current evidence adequate to demonstrate that the net health benefit of cytinicline with behavioral support is greater than that of varenicline with behavioral support?

Yes No

3. For people who smoke, is the current evidence adequate to demonstrate that the net health benefit of cytinicline with behavioral support is greater than that of electronic cigarettes containing nicotine with behavioral support?

Yes No

Patient Population for questions 4-5: *Individuals who are interested in quitting smoking electronic cigarettes (vaping) that contains nicotine*

4. For people who vape with nicotine, is the current evidence adequate to demonstrate that the net health benefit of cytinicline with behavioral support is greater than that of behavioral support alone?

Yes No

5. For people who vape with nicotine, is the current evidence adequate to demonstrate that the net health benefit of cytinicline with behavioral support is greater than that of varenicline with behavioral support?

Yes No

Benefits Beyond Health and Special Ethical Priorities

Patient Population for questions 6-11: Adults who are interested in quitting cigarettes

To help inform judgments of overall long-term value for money, please indicate your level of agreement with the following statements:

1=Strongly Disagree; 2=Disagree; 3=Neutral; 4=Agree; 5=Strongly Agree

6. There is substantial unmet need despite currently available treatments.
7. This condition is of substantial relevance for people from a racial/ethnic group that has not been equitably served by the healthcare system.

To help inform judgments of overall long-term value for money, please indicate your level of agreement with the following statements based on the relative effects of cytisinicline versus varenicline:

1=Strongly Disagree; 2=Disagree; 3=Neutral; 4=Agree; 5=Strongly Agree

8. The treatment is likely to produce substantial improvement in caregivers' quality of life and/or ability to pursue their own education, work, and family life.
9. The treatment offers a substantial opportunity to improve access to effective treatment by means of its mechanism of action or method of delivery.
10. Other: The treatment may increase acceptability and thus uptake among a subset of people who smoke because cytisinicline is derived from the seeds of an acacia plant, and can be marketed as a 'natural medicine'.

Long-Term Value for Money

11. Given the available evidence on comparative clinical effectiveness and incremental cost effectiveness, and considering benefits beyond health and special ethical priorities, what is the long-term value for money of cytisinicline compared to varenicline at current pricing?*
- a. High long-term value for money at current pricing
- b. Intermediate long-term value for money at current pricing
- c. Low long-term value for money at current pricing

**This vote will only be taken if a price becomes available for cytisinicline.*